Imvaq Therapeutics signs a Service and Commercial Product License to use ProBioGen’s AGE1.CR® Vaccine Manufacturing Platform
Berlin, Germany and New York, USA, January 6, 2022:
ProBioGen AG is delighted to announce the execution of a service and commercial product license agreement with Imvaq Therapeutics, a biotech company developing innovative cancer immunotherapies.…